University of Hyderabad (UoH) and Krismo Biosciences Private Limited, a biotechnology start-up incubated at ASPIRE-BioNEST, on Saturday announced their collaboration. The duo aim at developing next-generation therapies for inflammatory diseases and serious infectious conditions.
According to an official release, the key focus will be on the design of antibody-based therapies to effectively combat viral infections, including Dengue, COVID-19 and Influenza, as well as potent toxins produced by harmful bacteria responsible for debilitating conditions like gas gangrene.
The agreement outlines a collaborative approach to develop novel therapeutics, encompassing preclinical toxicology and non-GLP studies, with the shared goal of applying for relevant research grants, it said.
At the agreement signing ceremony, Nooruddin Khan of Department of Animal Biology (UoH) said: “The partnership represents the best of both worlds — academic excellence and industry innovation — coming together to address urgent healthcare challenges.”
Krishna Mohan of Krismo Biosciences said the collaboration would yield practical, affordable and impactful solutions for patients.
The initiative was facilitated by the university’s Technology Enabling Centre (UoH-TEC) established with support from the Department of Science and Technology, Government of India.
UoH-TEC project coordinator S. Rajagopal highlighted the Centre’s role in encouraging collaborations.
“We are actively encouraging our faculty members to translate their valuable knowledge into tangible technologies and products that can critically address pressing societal needs,” he stated.
He affirmed the TEC’s commitment to connecting academic innovators with established industry partners to bring innovations to the forefront.
Published – May 03, 2025 06:09 pm IST